Área Sanitaria da Coruña e Cee
Área sanitaria
Pablo
García Pavía
Publicacións nas que colabora con Pablo García Pavía (83)
2024
-
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The New England journal of medicine, Vol. 390, Núm. 20, pp. 1849-1861
-
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives
Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651
-
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy
JACC: Clinical Electrophysiology, Vol. 10, Núm. 6, pp. 1178-1190
-
Pregnancy in women with dilated cardiomyopathy genetic variants
Revista Espanola de Cardiologia
-
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
ESC Heart Failure
-
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy
Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548
-
Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction
Circulation: Genomic and Precision Medicine, Vol. 17, Núm. 2, pp. E004404
2023
-
2023 ESC Guidelines for the management of cardiomyopathies
European heart journal, Vol. 44, Núm. 37, pp. 3503-3626
-
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53
-
Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo
JACC: Cardiovascular Imaging, Vol. 16, Núm. 12, pp. 1567-1580
-
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure
European Heart Journal, Vol. 44, Núm. 48, pp. 5064-5073
-
Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation
European heart journal. Cardiovascular Imaging, Vol. 25, Núm. 1, pp. 75-85
-
Linee guida ESC 2023 per il trattamento delle cardiomiopatie elaborate dalla task force per il trattamento delle cardiomiopatie della Società Europea di Cardiologia (ESC)
Giornale italiano di cardiologia (2006), Vol. 24, Núm. 11, pp. 1e-127e
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45
-
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain
Amyloid, Vol. 30, Núm. 2, pp. 199-207
-
Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants
Circulation: Genomic and Precision Medicine, Vol. 16, Núm. 5, pp. 434-441
2022
-
Characterization of hereditary transthyretin cardiac amyloidosis in Spain
Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 488-495
-
Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy
Journal of the American College of Cardiology, Vol. 80, Núm. 12, pp. 1115-1126